Drug intelligence / Profile preview

DenovoDerm

Development stage: Phase 1
Lead developer: Cutiss
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

DenovoDerm is an autologous tissue-engineered dermal substitute designed for the treatment of various skin defects, including burn injuries, soft tissue injuries, skin necrosis, scars, congenital giant nevus, and skin tumors. It is developed to improve skin regeneration by providing a dermal matrix for healing. The product's evaluation focuses on its safety and the quantitative analysis of extracellular matrix components, such as type III collagen and laminin 5, which play crucial roles in skin regeneration.

Beyond the preview

Go deeper on DenovoDerm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DenovoDerm.

Explore the full profile